85 results on '"Fung, Chunkit"'
Search Results
2. Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy
- Author
-
Sanchez, Victoria A., Dinh, Jr., Paul C., Rooker, Jennessa, Monahan, Patrick O., Althouse, Sandra K., Fung, Chunkit, Sesso, Howard D., Einhorn, Lawrence H., Dolan, M. Eileen, Frisina, Robert D., and Travis, Lois B.
- Published
- 2023
- Full Text
- View/download PDF
3. How to Manage Cisplatin-Based Chemotherapy–Related Cardiovascular Disease in Patients With Testicular Cancer
- Author
-
Kadambi, Sindhuja, Clasen, Suparna C., and Fung, Chunkit
- Published
- 2022
- Full Text
- View/download PDF
4. Exemestane Treatment in a Male Patient With Concurrent Breast and Prostate Cancers: A Case Report.
- Author
-
Fitzgerald, Bryan P., Magnuson, Allison, and Fung, Chunkit
- Subjects
MALE breast cancer ,PROSTATE cancer patients ,PROGESTERONE receptors ,PROSTATE-specific antigen ,ESTROGEN receptors ,PROSTATE cancer ,HORMONE receptor positive breast cancer - Abstract
BACKGROUND: Concurrent breast and prostate cancers in male patients is considerably rare. The first-line treatments for estrogen receptor (ER)-positive, progesterone receptor (PR)-positive breast cancer and prostate cancer include hormonal therapy, albeit they target different hormonal pathways. DISCUSSION: We present an 81-year-old man with concurrent stage IIB ER-positive, PR-positive breast cancer and metastatic prostate cancer who initially received letrozole and leuprolide. After concerns for progression of his breast cancer while receiving letrozole, the patient’s therapy was switched to exemestane, a steroidal structurally different aromatase inhibitor. His testosterone and prostate-specific antigen levels increased after the initiation of treatment with exemestane, and subsequently decreased after the discontinuation of exemestane treatment. CONCLUSION: Our case report shows that treatment with exemestane should be avoided in male patients with concurrent breast and prostate cancers as a result of the progression of prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
5. High‐dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT.
- Author
-
Peppone, Luke J., Kleckner, Amber S., Fung, Chunkit, Puzas, J. Edward, Reschke, Jennifer E., Culakova, Eva, Inglis, Julia, Kamen, Charles, Friedberg, Jonathan W., Janelsins, Michelle, Mustian, Karen, Heckler, Charles E., and Mohile, Supriya
- Subjects
FEMUR neck ,ANDROGEN deprivation therapy ,PROSTATE cancer patients ,BONE density ,DUAL-energy X-ray absorptiometry ,BONE growth ,TERIPARATIDE ,ANDROGEN receptors - Abstract
Background: Androgen deprivation therapy (ADT) inhibits prostate cancer growth. However, ADT causes loss of bone mineral density (BMD) and an increase in fracture risk; effective interventions for ADT‐induced bone loss are limited. Methods: A phase 2 randomized controlled trial investigated the feasibility, safety, and preliminary efficacy of high‐dose weekly vitamin D (HDVD, 50,000 IU/week) versus placebo for 24 weeks in patients with prostate cancer receiving ADT, with all subjects receiving 600 IU/day vitamin D and 1000 mg/day calcium. Participants were ≥60 years (mean years, 67.7), had a serum 25‐hydroxyvitamin D level <32 ng/mL, and initiated ADT within the previous 6 months. At baseline and after intervention, dual‐energy x‐ray absorptiometry was used to assess BMD, and levels of bone cell, bone formation, and resorption were measured. Results: The HDVD group (N = 29) lost 1.5% BMD at the total hip vs. 4.1% for the low‐dose group (N = 30; p =.03) and 1.7% BMD at the femoral neck vs. 4.4% in the low‐dose group (p =.06). Stratified analyses showed that, for those with baseline 25‐hydroxyvitamin D level <27 ng/mL, the HDVD group lost 2.3% BMD at the total hip vs 7.1% for the low‐dose group (p <.01). Those in the HDVD arm showed significant changes in parathyroid hormone (p <.01), osteoprotegerin (p < 0.01), N‐terminal telopeptide of type 1 collagen (p < 0.01) and C‐terminal telopeptide of type 1 collagen (p < 0.01). No difference in adverse events or toxicity was noted between the groups. Conclusions: HDVD supplementation significantly reduced hip and femoral neck BMD loss, especially for patients with low baseline serum 25‐hydroxyvitamin D levels, although demonstrating safety and feasibility in prostate cancer patients on ADT. Patients with prostate cancer on androgen deprivation therapy often suffer rapid bone loss during the initiation of treatment. Supplementation with high‐dose vitamin D (50,000 IU/week plus 800 IU/day) significantly and safely decreased the amount of bone loss compared with vitamin D supplementation using the recommended daily allowance (800 IU/day). [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Comprehensive Audiologic Analyses After Cisplatin-Based Chemotherapy.
- Author
-
Sanchez, Victoria A., Dinh Jr, Paul C., Monahan, Patrick O., Althouse, Sandra, Rooker, Jennessa, Sesso, Howard D., Dolan, M. Eileen, Weinzerl, Mandy, Feldman, Darren R., Fung, Chunkit, Einhorn, Lawrence H., Frisina, Robert D., and Travis, Lois B.
- Published
- 2024
- Full Text
- View/download PDF
7. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
- Author
-
Cascallar, Diana Vera, Varela, Mirta, Lazzaro, Mauricio Fernandez, Kaen, Diego Lucas, Gatica, Gabriela, Flores, David Hugo, Falco, Agustin, Molina, Matias, Van Aelst, Filip, Vulsteke, Christof, Sautois, Brieuc, Machiels, Jean-Pascal, Schallier, Denis, Brust, Leandro, Rapatoni, Liane, Azevedo, Sergio J, Marinho, Gisele, Soares, Joao Paulo Holanda, Dzik, Carlos, Almeida Silva, Jamile, Fay, Andre Poisl, Gingerich, Joel, Fradet, Yves, Ferrario, Cristiano, Potvin, Kylea, Vanhuyse, Marie, Abdelsalam, Mahmoud, Cheng, Susanna, Caglevic, Christian, Reyes, Felipe, Leal, Jose Luis, Francisco, Francisco, Ibanez, Carolina, Joly, Florence, Laguerre, Brigitte, Ladoire, Sylvain, Flechon, Aude, Topart, Delphine, Huillard, Olivier, Oudard, Stéphane, Gross-Goupil, Marine, Culine, Stephane, Loriot, Yohann, Gravis, Gwenaelle, Reichardt, Peter, Retz, Margitta, Herden, Jan, Pfister, David, Ohlman, Carsten, Stoeckle, Michael, Wirth, Manfred, Lorch, Anja, Niegisch, Guenter, Goebell, Peter J, Boegemann, Martin, Merseburger, Axel, Gakis, Georgios, Bedke, Jens, Neisius, Andreas, Thomas, Christian, Hoefner, Thomas, Telekes, Andras, Kosa, Judit Erzsebet, Revesz, Janos, Bodoky, Gyorgy, Csoszi, Tibor, Csejtei, Andras, Geczi, Lajos, Ruzsa, Agnes, Kolonics, Zsuzsanna, Erfan, Jozsef, McDermott, Ray, Bambury, Richard, Sella, Avishay, Frank, Stephen Jay, Kejzman, Daniel, Goldman, Olesya, Rosenbaum, Eli, Peer, Avivit, Berger, Raanan, Rouvinov, Keren, Sarid, David, Fukasawa, Satoshi, Arai, Gaku, Yamaguchi, Akito, Yokomizo, Akira, Takayama, Tatsuya, Kinoshita, Hidefumi, Kikuchi, Eiji, Mizuno, Ryuichi, Fujii, Yasuhisa, Sassa, Naoto, Matsukawa, Yoshihisa, Fujimoto, Kiyohide, Matsubara, Nobuaki, Tanikawa, Toshiki, Tomita, Yoshihiko, Nishimura, Kazuo, Tsujihata, Masao, Oyama, Masafumi, Masumori, Naoya, Kanayama, Hiroomi, Takano, Toshimi, Miura, Yuji, Miyazaki, Jun, Joraku, Akira, Kimura, Tomokazu, Yamamoto, Yoshiaki, Kobayashi, Kazuki, De Wit, Ronald, Aarts, Maureen, Gerritsen, Winald, Los, Maartje, Beerepoot, Laurens, Izmailov, Adel, Gorelov, Sergey Igorevich, Alekseev, Boris Yakovlevich, Semenov, Andrey, Kostorov, Vladimir Anatolyevich, Alekseev, Sergey M, Zyryanov, Alexander, Oschepkov, Vasiliy Nikolaevich, Shidin, Vladimir Aleksandrovich, Vladimirov, Vladimir Ivanovich, Gafanov, Rustem Airatovich, Karlov, Petr Alexandrovich, Anderson, David Brian, Shepherd, Lucinda, Cohen, Graham Lawrence, Rapoport, Bernardo Louis, Ruff, Paul, Lee, Nari, Bae, Woo Kyun, Lee, Hyo Jin, Herranz, Urbano Anido, Rodriguez-Vida, Alejo, Morales Barrera, Rafael, Grande, Enrique, Alonso Gordoa, Teresa, Guma Padro, Josep, Gauna, Daniel Castellano, Arranz, Jose Angel, Munoz Langa, Jose, Sarrio, Regina Girones, Montesa Pino, Alvaro, Juan Fita, Maria Jose, Su, Yu-Li, Lin, Yung-Chang, Su, Wen-Pin, Shen, Ying-Chun, Chang, Yen-Hwa, Huang, Yi-Hsiu, Sriuranpong, Virote, Chansriwong, Phichai, Srimuninnimit, Vichien, Danchaivijitr, Pongwut, Abali, Huseyin, Yavuz, Sinan, Ozyilkan, Ozgur, Sendur, Mehmet Ali Nahit, Ekenel, Meltem, Ozguroglu, Mustafa, Arslan, Cagatay, Gunduz, Seyda, Ozdogan, Mustafa, Birtle, Alison, Powles, Thomas, Huddart, Robert, de Santis, Maria, Zarkar, Anjali, Evans, Linda, Hussain, Syed, DiSimone, Christopher, Muina, Antonio F, Schlegel, Peter, Jhangiani, Haresh S, Harrison, Michael, Slater, Dennis E, Wright, David, Percent, Ivor J, Lin, Jianqing, Hwang, Clara, Mamtani, Ronac, Gupta, Sumati, Bajaj, Madhuri, Galamaga, Robert, Eklund, John, Wallace, James, Shtivelband, Mikhail, Suh, Jason Jung-Gon, Burhani, Nafisa, Eadens, Matthew, Gunturu, Krishna, Burgess, Earle, Wong, John, Chaudhry, Arvind, Van Veldhuizen, Peter, Graff, Stephanie, Thomas, Christian A, Schnadig, Ian D, Carneiro, Benedito, Hussain, Maha, Morgans, Alicia, Fitzharris, John T, Oliff, Ira A, Vuky, Jacqueline, Hauke, Ralph, Baron, Ari, Joshi, Monika, Bolemon, Britt H, Jiang, Peter, Mega, Anthony E, Markus, Maurice, Pfanzelter, Nicklas, Lawler, William Eyre, Cobb, Patrick Wayne, Courtright, Jay G, Jain, Sharad, Doshi, Gurjyot, Gunuganti, Vijay K, Sartor, Oliver Alton, Cole, Scott W, Babiker, Hani, Uchio, Edward M, Drakaki, Alexandra, Mannuel, Heather D, Alva, Ajjai, Guancial, Elizabeth, Fung, Chunkit, Charles, Anthony, Amato, Robert J, Arriaga, Yull, Bowman, Isaac, Ades, Steven, Dreicer, Robert, Yu, Evan, Quinn, David I, Fleming, Mark, Csőszi, Tibor, Özgüroğlu, Mustafa, Géczi, Lajos, Cheng, Susanna Y-S, Oudard, Stephane, Fléchon, Aude, Yu, Evan Y, Nam, Kijoeng, Imai, Kentaro, and Homet Moreno, Blanca
- Published
- 2021
- Full Text
- View/download PDF
8. The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Women’s Health Initiative
- Author
-
Yung, Rachel, Ray, Roberta M., Roth, Joshua, Johnson, Lisa, Warnick, Greg, Anderson, Garnet L., Kroenke, Candyce H., Chlebowski, Rowan T., Simon, Michael S., Fung, Chunkit, Pan, Kathy, Wang, Di, Barrington, Wendy E., and Reding, Kerryn W.
- Published
- 2020
- Full Text
- View/download PDF
9. Impact of pain and adverse health outcomes on long-term US testicular cancer survivors.
- Author
-
Dinh, Paul C, Monahan, Patrick O, Fosså, Sophie D, Sesso, Howard D, Feldman, Darren R, Dolan, M Eileen, Nevel, Kathryn, Kincaid, John, Vaughn, David J, Martin, Neil E, Sanchez, Victoria A, Einhorn, Lawrence H, Frisina, Robert, Fung, Chunkit, Kroenke, Kurt, and Travis, Lois B
- Subjects
TESTICULAR cancer ,CANCER survivors ,PERIPHERAL vascular diseases ,PAIN ,NEURALGIA ,MENTAL health ,FUNCTIONAL status - Abstract
Background No study has quantified the impact of pain and other adverse health outcomes on global physical and mental health in long-term US testicular cancer survivors or evaluated patient-reported functional impairment due to pain. Methods Testicular cancer survivors given cisplatin-based chemotherapy completed validated surveys, including Patient-Reported Outcomes Measurement Information System v1.2 global physical and mental health, Patient-Reported Outcomes Measurement Information System pain questionnaires, and others. Multivariable linear regression examined relationships between 25 adverse health outcomes with global physical and mental health and pain-interference scores. Adverse health outcomes with a β ^ of more than 2 are clinically important and reported below. Results Among 358 testicular cancer survivors (median age = 46 years, interquartile range [IQR] = 38–53 years; median time since chemotherapy = 10.7 years, IQR = 7.2–16.0 years), median adverse health outcomes number was 5 (IQR = 3–7). A total of 12% testicular cancer survivors had 10 or more adverse health outcomes, and 19% reported chemotherapy-induced neuropathic pain. Increasing adverse health outcome numbers were associated with decreases in physical and mental health (P < .0001 each). In multivariable analyses, chemotherapy-induced neuropathic pain ( β ^ = −3.72; P = .001), diabetes ( β ^ = −4.41; P = .037), obesity ( β ^ = −2.01; P = .036), and fatigue ( β ^ = −8.58; P < .0001) were associated with worse global mental health, while being married or living as married benefited global mental health ( β ^ = 3.63; P = .0006). Risk factors for pain-related functional impairment included lower extremity location ( β ^ = 2.15; P = .04) and concomitant peripheral artery disease ( β ^ = 4.68; P < .001). Global physical health score reductions were associated with diabetes ( β ^ = −3.81; P = .012), balance or equilibrium problems ( β ^ = −3.82; P = .003), cognitive dysfunction ( β ^ = −4.43; P < .0001), obesity ( β ^ = −3.09; P < .0001), peripheral neuropathy score ( β ^ = −2.12; P < .0001), and depression ( β ^ = −3.17; P < .0001). Conclusions Testicular cancer survivors suffer adverse health outcomes that negatively impact long-term global mental health, global physical health, and pain-related functional status. Clinically important factors associated with worse physical and mental health identify testicular cancer survivors requiring closer monitoring, counseling, and interventions. Chemotherapy-induced neuropathic pain must be addressed, given its detrimental impact on patient-reported functional status and mental health 10 or more years after treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Adolescent and Young Adult Germ Cell Tumors: Epidemiology, Genomics, Treatment, and Survivorship.
- Author
-
Travis, Lois B., Feldman, Darren R., Fung, Chunkit, Poynter, Jenny N., Lockley, Michelle, and Frazier, A. Lindsay
- Published
- 2024
- Full Text
- View/download PDF
11. Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score
- Author
-
Sesso, Howard D., Beard, Clair J., Curreri, Stephanie, Travis, Lois B., Einhorn, Lawrence H., Brames, Mary Jacqueline, Norton, Kelli, Feldman, Darren R., Oeffinger, Kevin C., Jacobsen, Erin, Silber, Deborah, Hamilton, Rob, Anson-Cartwright, Lynn, Cox, Nancy J., Dolan, M. Eileen, Vaughn, David J., Jacobs, Linda, Panzer, Sarah Lena, Pucci, Donna, Baker, Debbie, Casaceli, Cindy, Fung, Chunkit, Johnson, Eileen, Sahasrabudhe, Deepak, Frisina, Robert D., Bosl, George, Fossa, Sophie D., Gospodarowicz, Mary, Robison, Leslie L., Lipshultz, Steven E., Ardeshir-Rouhani-Fard, Shirin, Monahan, Patrick, Williams, Annalynn M., Hamilton, Robert J., Cook, Ryan, and Zaid, Mohammad Abu
- Published
- 2018
- Full Text
- View/download PDF
12. State of Cancer Care in America: Achieving Cancer Health Equity Among Sexual and Gender Minority Communities.
- Author
-
Kamen, Charles S., Dizon, Don S., Fung, Chunkit, Pratt-Chapman, Mandi L., Agulnik, Mark, Fashoyin-Aje, Lola A., Jeames, Sanford E., Merrill, Janette K., Smith, Kimberly T., and Maingi, Shail
- Subjects
DIVERSITY & inclusion policies ,SOCIAL support ,DISCRIMINATION (Sociology) ,COMMUNITIES ,MEDICAL care ,ORGANIZATIONAL change ,LABOR supply ,SEXUAL minorities ,LGBTQ+ people ,QUALITY assurance ,INFORMATION resources ,HEALTH equity ,PATIENT education ,CANCER patient medical care ,HEALTH promotion - Abstract
In 2017, ASCO issued the position statement, Strategies for Reducing Cancer Health Disparities Among Sexual and Gender Minority Populations, outlining five areas of recommendations to address the needs of both sexual and gender minority (SGM, eg, LGBTQ1) populations affected by cancer and members of the oncology workforce who identify as SGM: (1) patient education and support; (2) workforce development and diversity; (3) quality improvement strategies; (4) policy solutions; and (5) research strategies. In 2019, ASCO convened the SGM Task Force to help actualize the recommendations of the 2017 position statement. The percentage of the US population who publicly identify as SGM has increased dramatically over the past few years. Although increased national interest in SGM health equity has accompanied a general interest in research, policy change, and education around diversity, equity, and inclusion, resulting from public concern over discrimination in health care against Black, Indigenous, and People of Color, this has been accompanied by a surge in discriminatory legislation directly impacting the SGM community. Although much progress has been made in advancing SGM cancer health equity since 2017, more progress is needed to reduce disparities and advance equity. The five focus areas outlined in the 2017 ASCO position statement remain relevant, as we must continue to promote and advance equity in quality improvement, workforce development, patient care, research, and SGM-affirming policies. This article reports on the progress toward reducing SGM cancer disparities and achieving equity across these five areas and identifies future directions for the work that still remains. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
13. Exercise Recommendations for the Management of Symptoms Clusters Resulting From Cancer and Cancer Treatments
- Author
-
Mustian, Karen M., Cole, Calvin L., Lin, Po Ju, Asare, Matt, Fung, Chunkit, Janelsins, Michelle C., Kamen, Charles S., Peppone, Luke J., and Magnuson, Allison
- Published
- 2016
- Full Text
- View/download PDF
14. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial
- Author
-
Kleckner, Ian R., Kamen, Charles, Gewandter, Jennifer S., Mohile, Nimish A., Heckler, Charles E., Culakova, Eva, Fung, Chunkit, Janelsins, Michelle C., Asare, Matthew, Lin, Po-Ju, Reddy, Pavan S., Giguere, Jeffrey, Berenberg, Jeffrey, Kesler, Shelli R., and Mustian, Karen M.
- Published
- 2017
- Full Text
- View/download PDF
15. Association of falls with health-related quality of life (HRQOL) in older cancer survivors: A population based study
- Author
-
Pandya, Chintan, Magnuson, Allison, Dale, William, Lowenstein, Lisa, Fung, Chunkit, and Mohile, Supriya G.
- Published
- 2016
- Full Text
- View/download PDF
16. Novel physical activity interventions for older patients with prostate cancer on hormone therapy: A pilot randomized study
- Author
-
Sajid, Saleha, Dale, William, Mustian, Karen, Kotwal, Ashwin, Heckler, Charles, Porto, Michelle, Fung, Chunkit, and Mohile, Supriya G.
- Published
- 2016
- Full Text
- View/download PDF
17. Long-term Morbidity of Testicular Cancer Treatment
- Author
-
Fung, Chunkit, Fossa, Sophie D., Williams, Annalynn, and Travis, Lois B.
- Published
- 2015
- Full Text
- View/download PDF
18. Impact of Bladder Cancer on Health Related Quality of Life in 1,476 Older Americans: A Cross-Sectional Study
- Author
-
Fung, Chunkit, Pandya, Chintan, Guancial, Elizabeth, Noyes, Katia, Sahasrabudhe, Deepak M., Messing, Edward M., and Mohile, Supriya G.
- Published
- 2014
- Full Text
- View/download PDF
19. Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study
- Author
-
Shah, Amishi Y., Karam, Jose A., Malouf, Gabriel G., Rao, Priya, Lim, Zita D., Jonasch, Eric, Xiao, Lianchun, Gao, Jianjun, Vaishampayan, Ulka N., Heng, Daniel Y., Plimack, Elizabeth R., Guancial, Elizabeth A., Fung, Chunkit, Lowas, Stefanie R., Tamboli, Pheroze, Sircar, Kanishka, Matin, Surena F., Kimryn Rathmell, W., Wood, Christopher G., and Tannir, Nizar M.
- Published
- 2017
- Full Text
- View/download PDF
20. Cardiovascular Risks in Testicular Cancer: Assessment, Prevention, and Treatment.
- Author
-
Clasen, Suparna C., Fung, Chunkit, Sesso, Howard D., and Travis, Lois B.
- Abstract
Purpose of Review: Testicular cancer (TC) is the leading cancer in men between 18 and 39 years of age. Current treatment involves tumor resection followed by surveillance and/or one or more lines of cisplatin-based chemotherapy (CBCT) and/or bone marrow transplant (BMT). Ten years after treatment, CBCT has been associated with significant atherosclerotic cardiovascular disease (CVD) including myocardial infarction (MI), stroke, and heightened rates of hypertension, dyslipidemia, diabetes mellitus, and metabolic syndrome (MetS). Additionally, low testosterone levels and hypogonadism contribute to MetS and may further drive CVD. Recent Findings: CVD in TCS has been associated with worse physical functioning accompanied by role limitations, decreased energy, and decreased overall health. Exercise may play a role in ameliorating these effects. Summary: Systematic CVD screening practices are needed at TC diagnosis and in survivorship. We encourage a multidisciplinary partnership between primary care physicians, cardiologists, cardio-oncologists, medical oncologists, and survivorship providers to address these needs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Patient-Reported Functional Impairment Due to Hearing Loss and Tinnitus After Cisplatin-Based Chemotherapy.
- Author
-
Sanchez, Victoria A., Shuey, Megan M., Dinh Jr, Paul C., Monahan, Patrick O., Fosså, Sophie D., Sesso, Howard D., Dolan, M. Eileen, Einhorn, Lawrence H., Vaughn, David J., Martin, Neil E., Feldman, Darren R., Kroenke, Kurt, Fung, Chunkit, Frisina, Robert D., and Travis, Lois B.
- Published
- 2023
- Full Text
- View/download PDF
22. Lack of hydroxyurea‐associated mutagenesis in pediatric sickle cell disease patients.
- Author
-
Torous, Dorothea K., Avlasevich, Svetlana, Bemis, Jeffrey C., Howard, Thad, Ware, Russell E., Fung, Chunkit, Chen, Yuhchyau, Sahsrabudhe, Deepak, MacGregor, James T., and Dertinger, Stephen D.
- Subjects
SICKLE cell anemia ,MUTAGENESIS ,CHILD patients ,GENETIC mutation ,TESTICULAR cancer - Abstract
Hydroxyurea is approved for treating children and adults with sickle cell anemia (SCA). Despite its proven efficacy, concerns remain about its mutagenic and carcinogenic potential that hamper its widespread use. Cell culture‐ and animal‐based investigations indicate that hydroxyurea's genotoxic effects are due to indirect clastogenicity in select cell types when high dose and time thresholds are exceeded (reviewed by Ware & Dertinger, 2021). The current study extends these preclinical observations to pediatric patients receiving hydroxyurea for treatment of SCA. First, proof‐of‐principle experiments with testicular cancer patients exposed to a cisplatin‐based regimen validated the ability of flow cytometric blood‐based micronucleated reticulocyte (MN‐RET) and PIG‐A mutant reticulocyte (MUT RET) assays to detect clastogenicity and gene mutations, respectively. Second, these biomarkers were measured in a cross‐sectional study with 26 SCA patients receiving hydroxyurea and 13 SCA patients without exposure. Finally, a prospective study was conducted with 10 SCA patients using pretreatment blood samples and after 6 or 12 months of therapy. Cancer patients exposed to cisplatin exhibited increased MN‐RET within days of exposure, while the MUT RET endpoint required more time to reach maximal levels. In SCA patients, hydroxyurea induced MN‐RET in both the cross‐sectional and prospective studies. However, no evidence of PIG‐A gene mutation was found in hydroxyurea‐treated children, despite the fact that the two assays use the same rapidly‐dividing, highly‐exposed cell type. Collectively, these results reinforce the complementary nature of MN‐RET and MUT RET biomarkers, and indicate that hydroxyurea can be clastogenic but was not mutagenic in young patients with SCA. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. Comprehensive association analysis of speech recognition thresholds after cisplatin‐based chemotherapy in survivors of adult‐onset cancer.
- Author
-
Shahbazi, Mohammad, Zhang, Xindi, Dinh, Paul C., Sanchez, Victoria A., Trendowski, Matthew R., Shuey, Megan M., Nguyen, Tessa, Feldman, Darren R., Vaughn, David J., Fung, Chunkit, Kollmannsberger, Christian, Martin, Neil E., Einhorn, Lawrence H., Cox, Nancy J., Frisina, Robert D., Travis, Lois B., and Dolan, Mary Eileen
- Subjects
SPEECH perception ,CANCER survivors ,HEARING disorders ,GENETIC variation ,SMOKING statistics ,MOTOR neuron diseases ,SPEECH-language pathology ,SPEECH apraxia - Abstract
Purpose: Deficits in speech understanding constitute one of the most severe consequences of hearing loss. Here we investigate the clinical and genetic risk factors for symmetric deterioration of speech recognition thresholds (SRT) among cancer survivors treated with cisplatin. Methods: SRT was measured using spondaic words and calculating the mean of measurements for both ears with symmetric SRT values. For clinical associations, SRT‐based hearing disability (SHD) was defined as SRT≥15 dB hearing loss and clinical variables were derived from the study dataset. Genotyped blood samples were used for GWAS with rank‐based inverse normal transformed SRT values as the response variable. Age was used as a covariate in association analyses. Results: SHD was inversely associated with self‐reported health (p = 0.004). Current smoking (p = 0.002), years of smoking (p = 0.02), BMI (p < 0.001), and peripheral motor neuropathy (p = 0.003) were positively associated with SHD, while physical activity was inversely associated with SHD (p = 0.005). In contrast, cumulative cisplatin dose, peripheral sensory neuropathy, hypertension, and hypercholesterolemia were not associated with SHD. Although no genetic variants had an association p value < 5 × 10−8, 22 genetic variants were suggestively associated (p < 10−5) with SRT deterioration. Three of the top variants in 10 respective linkage disequilibrium regions were either positioned within the coding sequence or were eQTLs for genes involved in neuronal development (ATE1, ENAH, and ZFHX3). Conclusion: Current results improve our understanding of risk factors for SRT deterioration in cancer survivors. Higher BMI, lower physical activity, and smoking are associated with SHD. Larger samples would allow for expansion of the current findings on the genetic architecture of SRT. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. AGS and NIA bench‐to bedside conference summary: Cancer and cardiovascular disease.
- Author
-
Mohile, Supriya, Blaum, Caroline S., Abadir, Peter M., Dale, William, Forman, Daniel E., Fung, Chunkit, Holmes, Holly M., Moslehi, Javid, Mustian, Karen M., Rich, Michael W., and Whitson, Heather E.
- Subjects
CARDIOVASCULAR disease treatment ,TUMOR treatment ,HEART disease risk factors ,CAUSES of death ,CARDIOVASCULAR diseases risk factors ,CARDIOTOXICITY ,CLINICAL trials ,CANCER chemotherapy ,CONFERENCES & conventions ,MEDICAL care ,CELLULAR aging ,PATIENTS' attitudes ,AGING ,DECISION making ,PROFESSIONAL associations ,TUMORS ,COMORBIDITY ,DISEASE complications - Abstract
This report summarizes the presentations, discussions, and recommendations of the most recent American Geriatrics Society and National Institute on Aging research conference, "Cancer and Cardiovascular Disease," on October 18–19, 2021. The purpose of this virtual meeting was to address the interface between cancer and heart disease, which are the two leading causes of death among older Americans. Age‐related physiologic changes are implicated in the pathogenesis of both conditions. Emerging data suggest that cancer‐related cardiovascular disease (CVD) involves disrupted cell signaling and cellular senescence. The risk factors for CVD are also risk factors for cancer and an increased likelihood of cancer death, and people who have both cancer and CVD do more poorly than those who have only cancer or only CVD. Issues addressed in this bench‐to‐bedside conference include mechanisms of cancer and CVD co‐development in older adults, cardiotoxic effects of cancer therapy, and management of comorbid cancer and CVD. Presenters discussed approaches to ensure equitable access to clinical trials and health care for diverse populations of adults with CVD and cancer, mechanisms of cancer therapy cardiotoxicity, and management of comorbid CVD and cancer, including the role of patient values and preferences in treatment decisions. Workshop participants identified many research gaps and questions that could lead to an enhanced understanding of comorbid CVD and cancer and to better and more equitable management strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
25. Second Primary Head and Neck Cancer After Hodgkin Lymphoma: A Population-Based Study of 44,879 Survivors of Hodgkin Lymphoma
- Author
-
Chowdhry, Amit K., McHugh, Colin, Fung, Chunkit, Dhakal, Sughosh, Constine, Louis S., and Milano, Michael T.
- Published
- 2015
- Full Text
- View/download PDF
26. MP51-11 DOES HYPOGONADISM (OR LOW T) PRESENT DIFFERENTLY IN THE INFERTILE MALE?
- Author
-
Levey, Helen R., Kujreja, Janet, Ramasamay, Ranjith, Kucherov, Victor, Budnik, Justin, Fung, Chunkit, Gentile, David, and Obrien, Jeanne
- Published
- 2015
- Full Text
- View/download PDF
27. Medicare Accountable Care Organizations: Post-acute Care Use and Post-surgical Outcomes in Urologic Cancer Surgery.
- Author
-
Katragadda, Chinmayee, Fung, Chunkit, Yousefi-Nooraie, Reza, Cupertino, Paula, Joseph, Jean, Kim, Yeunkyung, and Li, Yue
- Subjects
- *
ACCOUNTABLE care organizations , *ONCOLOGIC surgery , *UROLOGICAL surgery , *MEDICARE , *MEDICAL care costs , *CANCER prognosis - Abstract
Objective: To evaluate association between Medicare accountable care organizations (ACOs) participation of hospitals on post-acute care (PAC) use and spending, and post-surgical outcomes in Medicare beneficiaries undergoing urologic cancer surgeries. Despite increasing prevalence of urologic cancer and surgical care contributing to a large proportion of total health care costs, and recent Medicare payment reforms such as accountable care organizations, the role of ACOs in urologic cancer care has been unexplored.Methods: We conducted a longitudinal analysis of 2011-2017 Medicare claims data to compare post-surgical outcomes between Medicare ACO and non-ACO patients before and after implementation of Medicare shared savings program (MSSP). Our outcomes of interest were Post-acute care (PAC) use (overall, institutional, and home health), Skilled Nursing Facility (SNF) length of stay and Medicare spending for SNF patients, 30-day and 90-day unplanned readmissions and complications after index procedure.Results: Study sample included a total of 334,514 Medicare patients undergoing bladder, prostate, kidney cancer surgeries at 524 Medicare ACO and 2066 non-ACO hospitals. For bladder cancer surgery, Medicare ACO participation was associated with significantly reduced overall post-acute care use, but not with changes in readmission or complication rate. For prostate cancer and kidney cancer surgery, we found no significant association between hospital participation in Medicare ACOs and PAC use or post-surgical outcomes.Conclusion: Hospital participation in MSSP ACOs leads to lower post-acute care use without compromising patient outcomes for Medicare beneficiaries undergoing bladder cancer surgery. Future research is needed to understand longer-term impact of ACO participation on urologic cancer surgery outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
28. Pharmacogenomics of cisplatin‐induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy.
- Author
-
Zhang, Xindi, Trendowski, Matthew R., Wilkinson, Emma, Shahbazi, Mohammad, Dinh, Paul C., Shuey, Megan M., Feldman, Darren R., Hamilton, Robert J., Vaughn, David J., Fung, Chunkit, Kollmannsberger, Christian, Huddart, Robert, Martin, Neil E., Sanchez, Victoria A., Frisina, Robert D., Einhorn, Lawrence H., Cox, Nancy J., Travis, Lois B., and Dolan, M. Eileen
- Subjects
TINNITUS ,HEARING disorders ,TESTICULAR cancer ,PERIPHERAL neuropathy ,PHARMACOGENOMICS ,GENOME-wide association studies ,GERM cell tumors ,TUMOR suppressor genes - Abstract
Purpose: Cisplatin is a critical component of first‐line chemotherapy for several cancers, but causes peripheral sensory neuropathy, hearing loss, and tinnitus. We aimed to identify comorbidities for cisplatin‐induced neurotoxicities among large numbers of similarly treated patients without the confounding effect of cranial radiotherapy. Methods: Utilizing linear and logistic regression analyses on 1680 well‐characterized cisplatin‐treated testicular cancer survivors, we analyzed associations of hearing loss, tinnitus, and peripheral neuropathy with nongenetic comorbidities. Genome‐wide association studies and gene‐based analyses were performed on each phenotype. Results: Hearing loss, tinnitus, and peripheral neuropathy, accounting for age and cisplatin dose, were interdependent. Survivors with these neurotoxicities experienced more hypertension and poorer self‐reported health. In addition, hearing loss was positively associated with BMIs at clinical evaluation and nonwork‐related noise exposure (>5 h/week). Tinnitus was positively associated with tobacco use, hypercholesterolemia, and noise exposure. We observed positive associations between peripheral neuropathy and persistent vertigo, tobacco use, and excess alcohol consumption. Hearing loss and TXNRD1, which plays a key role in redox regulation, showed borderline significance (p = 4.2 × 10−6) in gene‐based analysis. rs62283056 in WFS1 previously found to be significantly associated with hearing loss (n = 511), was marginally significant in an independent replication cohort (p = 0.06; n = 606). Gene‐based analyses identified significant associations between tinnitus and WNT8A (p = 2.5 × 10−6), encoding a signaling protein important in germ cell tumors. Conclusions: Genetics variants in TXNRD1 and WNT8A are notable risk factors for hearing loss and tinnitus, respectively. Future studies should investigate these genes and if replicated, identify their potential impact on preventive strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments.
- Author
-
Ardeshirrouhanifard, Shirin, Fossa, Sophie D., Huddart, Robert, Monahan, Patrick O., Fung, Chunkit, Song, Yiqing, Dolan, M. Eileen, Feldman, Darren R., Hamilton, Robert J., Vaughn, David, Martin, Neil E., Kollmannsberger, Christian, Dinh, Paul, Einhorn, Lawrence, Frisina, Robert D., and Travis, Lois B.
- Published
- 2022
- Full Text
- View/download PDF
30. Increased risk of high-grade prostate cancer among testicular cancer survivors.
- Author
-
Zhang, Hong, Yang, Hongmei, Bandyopadhyay, Sanjukta, Milano, Michael T., Fung, Chunkit, Messing, Edward M., and Chen, Yuhchyau
- Subjects
TESTICULAR cancer ,CANCER survivors ,PROSTATE cancer ,PROSTATE cancer patients ,CANCER diagnosis ,PROSTATE-specific antigen - Abstract
Introduction: Testicular cancer survivors (TCS) have an increased risk of additional cancers, including prostate cancer. Our understanding of the natural history of prostate cancer in testicular cancer survivors is very limited due to its rare incidence. Methods: Using the Surveillance, Epidemiology, and End Results (SEER) Registry from 1978 to 2011, we identified 282 TCS with subsequent prostate cancer and examined the tumor grade and clinical outcomes in contrast to men with primary prostate cancer in the general population. Results: TCS with a subsequent prostate cancer diagnosis were more likely to be diagnosed at a younger age than men with primary prostate cancer (65.2% vs. 37.6% for age ≤65, 34.8% vs. 62.4% for age >65, p<0.001) and were more likely to have grade III/IV tumors (46.2% vs. 37.0%, p<0.002). Longer latency between testicular and prostate cancer diagnoses was associated with a higher risk of grade III/IV (p<0.001) cancer. Despite the increased risk for high-grade tumors, 10-year prostate cancer-specific survival and overall survival were not significantly different between TCS and men with primary prostate cancer. Based on the available information in SEER, we found that prior history of radiotherapy for testicular cancer had no impact on tumor grade or survival outcomes. Conclusions: Prostate cancer in TCS was more likely to be diagnosed at a younger age and with higher grades. Risks of grade III/IV disease increased with longer latency between testicular and prostate cancer diagnoses. Radiotherapy for testicular cancer did not appear to have a significant impact on the outcome of subsequent prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
31. Testicular Cancer Survivorship: Looking Back to Move Forward.
- Author
-
Fung, Chunkit and Travis, Lois B
- Published
- 2021
- Full Text
- View/download PDF
32. Tobacco Dependence Treatment: Examining cessation effectiveness in oncology settings.
- Author
-
Mallaber, Patricia R., Fung, Chunkit, Strawderman, Myla, Knapp-Clevenger, Rhonda, and Williams, Geoffrey C.
- Subjects
- *
TREATMENT of drug addiction , *SMOKING cessation , *SPECIALTY hospitals , *INTERVIEWING , *CANCER treatment - Published
- 2021
- Full Text
- View/download PDF
33. Surviving Testicular Cancer: The Role of the Contralateral Testicle.
- Author
-
D'souza, Anishka, Van Veldhuizen, Peter, and Fung, Chunkit
- Published
- 2021
- Full Text
- View/download PDF
34. Cisplatin, environmental metals, and cardiovascular disease: an urgent need to understand underlying mechanisms.
- Author
-
Clasen, Suparna C., Dinh Jr, Paul C., Hou, Lifang, Fung, Chunkit, Sesso, Howard D., and Travis, Lois B.
- Published
- 2021
- Full Text
- View/download PDF
35. Relationship of Cisplatin-Related Adverse Health Outcomes With Disability and Unemployment Among Testicular Cancer Survivors.
- Author
-
Kerns, Sarah L, Fung, Chunkit, Fossa, Sophie D, Dinh, Paul C, Monahan, Patrick, Sesso, Howard D, Frisina, Robert D, Feldman, Darren R, Hamilton, Robert J, Vaughn, David, Martin, Neil, Huddart, Robert, Kollmannsberger, Christian, Sahasrabudhe, Deepak, Ardeshir-Rouhani-Fard, Shirin, Einhorn, Lawrence, and Travis, Lois B
- Subjects
CISPLATIN ,UNEMPLOYMENT ,TESTICULAR cancer - Abstract
Background Few data exist on the relationship of cisplatin-related adverse health outcomes (AHOs) with disability, unemployment, and self-reported health (SRH) among testicular cancer survivors (TCS). Methods A total of 1815 TCS at least 1 year postchemotherapy underwent clinical examination and completed questionnaires. Treatment data were abstracted from medical records. A cumulative burden of morbidity score (CBM
Pt ) encompassed the number and severity of platinum-related AHOs (peripheral sensory neuropathy [PSN], hearing loss, tinnitus, renal disease). Multivariable regression assessed the association of AHOs and CBMPt with employment status and SRH, adjusting for sociodemographic and clinical characteristics. Unemployment was compared with a male normative population of similar age, race, and ethnicity. Results Almost 1 in 10 TCS was out of work (2.4%, disability leave; 6.8%, unemployed) at a median age of 37 years (median follow-up = 4 years). PSN (odds ratio [OR] = 2.89, 95% confidence interval [CI] = 1.01 to 8.26, grade 3 vs 0, P = .048), renal dysfunction defined by estimated glomerular filtration rate (OR = 12.1, 95% CI = 2.06 to 70.8, grade 2 vs 0, P = .01), pain (OR = 10.6, 95% CI = 4.40 to 25.40, grade 2 or 3 vs 0, P < .001), and CBMPt (OR = 1.46, 95% CI = 1.03 to 2.08, P = .03) were associated with disability leave; pain strongly correlated with PSN (r2 = 0.40, P < .001). Statistically significantly higher percentages of TCS were unemployed vs population norms (age-adjusted OR = 2.67, 95% CI = 2.49 to 3.02, P < .001). PSN (OR = 2.44, 95% CI = 1.28 to 4.62, grade 3 vs 0, P = .006), patient-reported hearing loss (OR = 1.82, 95% CI = 1.04 to 3.17, grade 2 or 3 vs 0, P = .04), and pain (OR = 3.75, 95% CI = 2.06 to 6.81, grade 2 or 3 vs 0, P < .001) were associated with unemployment. Increasing severity of most cisplatin-related AHOs and pain were associated with statistically significantly worse SRH. Conclusions Our findings have important implications regarding treatment-associated productivity losses and socioeconomic costs in this young population. Survivorship care strategies should include inquiries about disability and unemployment status, with efforts made to assist affected TCS in returning to the workforce. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
36. Solid and Hematologic Neoplasms After Testicular Cancer: A US Population-Based Study of 24 900 Survivors.
- Author
-
Milano, Michael T, Dinh, Paul C, Yang, Hongmei, Zaid, Mohammad Abu, Fossa, Sophie D, Feldman, Darren R, Monahan, Patrick O, Travis, Lois B, and Fung, Chunkit
- Subjects
MEDICAL screening ,PLASMA cell diseases ,ACUTE myeloid leukemia - Abstract
Background No large US population-based study focusing on recent decades, to our knowledge, has comprehensively examined risks of second malignant solid and hematological neoplasms (solid-SMN and heme-SMN) after testicular cancer (TC), taking into account initial therapy and histological type. Methods Standardized incidence ratios (SIR) vs the general population and 95% confidence intervals (CI) for solid-SMN and heme-SMN were calculated for 24 900 TC survivors (TCS) reported to the National Cancer Institute's Surveillance, Epidemiology, and End Results registries (1973–2014). All statistical tests were two-sided. Results The median age at TC diagnosis was 33 years. Initial management comprised chemotherapy (n = 6340), radiotherapy (n = 9058), or surgery alone (n = 8995). During 372 709 person-years of follow-up (mean = 15 years), 1625 TCS developed solid-SMN and 228 (107 lymphomas, 92 leukemias, 29 plasma cell dyscrasias) developed heme-SMN. Solid-SMN risk was increased 1.06-fold (95% CI = 1.01 to 1.12), with elevated risks following radiotherapy (SIR = 1.13, 95% CI = 1.06 to 1.21) and chemotherapy (SIR = 1.36, 95% CI = 1.12 to 1.41) but not surgery alone (SIR = 0.83, 95% CI = 0.75 to 0.92). Corresponding risks for seminoma were 1.13 (95% CI = 1.06 to 1.21), 1.28 (95% CI = 1.02 to 1.58), and 0.87 (95% CI = 0.74 to 1.01) and for nonseminoma were 1.05 (95% CI = 0.67 to 1.56), 1.25 (95% CI = 1.08 to 1.43), and 0.80 (95% CI = 0.70 to 0.92), respectively. Thirty-year cumulative incidences of solid-SMN after radiotherapy, chemotherapy, and surgery alone were 16.9% (95% CI = 15.7% to 18.1%), 10.1% (95% CI = 8.8% to 11.5%), and 8.8% (95% CI = 7.8% to 9.9%), respectively (P < .0001). Increased leukemia risks after chemotherapy (SIR = 2.68, 95% CI = 1.70 to 4.01) were driven by statistically significant sevenfold excesses of acute myeloid leukemia 1 to 10 years after TC diagnosis. Risks for lymphoma and plasma cell dyscrasias were not elevated. Conclusions We report statistically significant excesses of solid-SMN affecting 1 in 6 TCS 30 years after radiotherapy, and 2.7-fold risks of leukemias after chemotherapy, mostly acute myeloid leukemia. Efforts to minimize chemotherapy and radiotherapy exposures for TC should continue. TCS should be counseled about cancer prevention and screening. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
37. Adverse Health Outcomes Among US Testicular Cancer Survivors After Cisplatin-Based Chemotherapy vs Surgical Management.
- Author
-
Agrawal, Vaibhav, Dinh, Paul C, Fung, Chunkit, Monahan, Patrick O, Althouse, Sandra K, Norton, Kelli, Cary, Clint, Einhorn, Lawrence, Fossa, Sophie D, Adra, Nabil, and Travis, Lois B
- Subjects
ADVERSE health care events ,TESTICULAR cancer treatment ,CISPLATIN ,CANCER chemotherapy ,OPERATIVE surgery ,CANCER patients ,TESTICULAR cancer - Abstract
We evaluated for the first time, to our knowledge, adverse health outcomes (AHOs) among US testicular cancer survivors (TCS) given chemotherapy (n = 381) vs surgery-only patients (n = 98) managed at a single institution, accounting for non-treatment-related risk factors to delineate chemotherapy's impact. Chemotherapy consisted largely of bleomycin-etoposide-cisplatin (BEP) administered in three or four cycles (BEPx3, n = 235; BEPx4, n = 82). Incidence of at least 3 AHOs was lowest in surgery-only TCS and increased with BEPx3, BEPx4, and other cisplatin-based regimens (12.2%, 40.8%, 52.5%, 54.8%; P < .0001). Multivariable modeling assessed associations of risk factors and treatment with hearing impairment, tinnitus, peripheral neuropathy, and Raynaud phenomenon. Risk for each AHO statistically increased with both increasing chemotherapy burden (P < .0001) and selected modifiable risk factors (P < .05): hypertension (odds ratio [OR] = 2.40) and noise exposure (OR ≥ 2.3) for hearing impairment; noise exposure for tinnitus (OR ≥ 1.69); peripheral vascular disease for neuropathy (OR = 8.72); and current smoking for Raynaud phenomenon (OR = 2.41). Clinicians should manage modifiable risk factors for AHOs among TCS. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
38. Effects of exercise on inflammation in patients receiving chemotherapy: a nationwide NCORP randomized clinical trial.
- Author
-
Kleckner, Ian R., Kamen, Charles, Cole, Calvin, Fung, Chunkit, Heckler, Charles E., Guido, Joseph J., Culakova, Eva, Onitilo, Adedayo A., Conlin, Alison, Kuebler, J. Philip, Mohile, Supriya, Janelsins, Michelle, and Mustian, Karen M.
- Subjects
CLINICAL trials ,EXERCISE ,ISOMETRIC exercise ,CANCER chemotherapy ,SERUM ,TREADMILL exercise - Abstract
Purpose: A growing body of research suggests that inflammation plays a role in many chemotherapy-related toxicities such as fatigue, anxiety, and neuropathy. Regular exercise can change levels of individual cytokines (e.g., reducing IL-6, increasing IL-10); however, it is not known whether exercise during chemotherapy affects relationships between cytokines (i.e., whether cytokine concentrations change collectively vs. independently). This study assessed how 6 weeks of exercise during chemotherapy affected relationships between changes in concentrations of several cytokines.Methods: This is a secondary analysis of a randomized trial studying 6 weeks of moderate-intensity walking and resistance exercise during chemotherapy compared with chemotherapy alone. At pre- and post-intervention, patients provided blood to assess serum concentrations of cytokines IL-1β, IL-6, IL-8, IL-10, and IFN-γ, and receptor sTNFR1. We investigated relationships between cytokines using the correlations between changes in cytokine concentrations from pre- to post-intervention.Results: We obtained complete data from 293 patients (149 randomized to exercise). Exercise strengthened the correlation between concentration changes of IL-10 and IL-6 (r = 0.44 in exercisers vs. 0.11 in controls; p = 0.001). We observed the same pattern for IL-10:IL-1β and IL-10:sTNFR1. Exercise also induced an anti-inflammatory cytokine profile, per reductions in pro-inflammatory IFN-γ (p = 0.044) and perhaps IL-1β (p = 0.099, trend-level significance).Conclusions: Our hypothesis-generating work suggests that regular exercise during 6 weeks of chemotherapy may cause certain cytokine concentrations to change collectively (not independently). This work enhances our understanding of relationships between cytokines and complements traditional analyses of cytokines in isolation. Future work should test for replication and relationships to patient outcomes.Trial Registration: Clinical Trials.gov, # NCT00924651, http://www.clinicaltrials.gov . [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
39. Effects of a Home‐based Exercise Program on Anxiety and Mood Disturbances in Older Adults with Cancer Receiving Chemotherapy.
- Author
-
Loh, Kah Poh, Kleckner, Ian R., Lin, Po‐Ju, Mohile, Supriya G., Canin, Beverly E., Flannery, Marie A., Fung, Chunkit, Dunne, Richard F., Bautista, Javier, Culakova, Eva, Kleckner, Amber S., Peppone, Luke J., Janelsins, Michelle, McHugh, Colin, Conlin, Alison, Cho, Jonathan K., Kasbari, Sameer, Esparaz, Benjamin T., Kuebler, J. Philip, and Mustian, Karen M.
- Subjects
ALTERNATIVE treatment for anxiety ,AFFECTIVE disorders ,MEDICAL rehabilitation ,CANCER chemotherapy ,CANCER patient psychology ,EMOTIONS ,EXERCISE therapy ,HOME care services ,PREVENTION - Abstract
BACKGROUND/OBJECTIVE: Exercise interventions improve anxiety and mood disturbances in patients with cancer. However, studies are limited in older adults with cancer. We assessed the effects of exercise on anxiety, mood, and social and emotional well‐being in older patients with cancer during their first 6 weeks of chemotherapy. DESIGN: Exploratory secondary analysis of a randomized controlled trial (RCT). SETTING: Community oncology practices. PARTICIPANTS: Older patients (aged 60 years or older) undergoing chemotherapy (N = 252). INTERVENTION: Patients were randomized to Exercise for Cancer Patients (EXCAP) or usual care (control) for the first 6 weeks of chemotherapy. EXCAP is a home‐based, low‐ to moderate‐intensity progressive walking and resistance training program. MEASUREMENTS: Analysis of covariance, with study arm as the factor, baseline value as the covariate, and study arm × baseline interaction, was used to evaluate arm effects on postintervention anxiety (State Trait Anxiety Inventory [STAI]), mood (Profile of Mood States [POMS]), and social and emotional well‐being (Functional Assessment of Cancer Therapy–General subscales) after 6 weeks. RESULTS: Median age was 67 years; 77% had breast cancer. Statistically significant group differences were observed in the STAI score (P = .001), POMS score (P = .022), social well‐being (P = .002), and emotional well‐being (P = .048). For each outcome, EXCAP patients with worse baseline scores had larger improvements at 6 weeks; these improvements were clinically significant for STAI score and social well‐being. CONCLUSIONS: Among older cancer patients receiving chemotherapy, a 6‐week structured exercise program improved anxiety and mood, especially among those participants with worse baseline symptoms. Additional RCTs are needed to confirm these findings and evaluate the appropriate exercise prescription for managing anxiety, mood, and well‐being in this patient population. J Am Geriatr Soc 67:1005–1011, 2019. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
40. Increased Risk of Cardiovascular Sequelae in Survivors of Male Germ Cell Cancer.
- Author
-
Clasen, Suparna C., Fung, Chunkit, Dinh, Paul C., Travis, Lois B., and Dinh, Paul C Jr
- Published
- 2020
- Full Text
- View/download PDF
41. Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.
- Author
-
Kerns, Sarah L., Fung, Chunkit, Monahan, Patrick O., Ardeshir-Rouhani-Fard, Shirin, Abu Zaid, Mohammad I., Williams, AnnaLynn M., Stump, Timothy E., Sesso, Howard D., Feldman, Darren R., Hamilton, Robert J., Vaughn, David J., Beard, Clair, Huddart, Robert A., Kim, Jeri, Kollmannsberger, Christian, Sahasrabudhe, Deepak M., Cook, Ryan, Fossa, Sophie D., Einhorn, Lawrence H., and Travis, Lois B.
- Published
- 2018
- Full Text
- View/download PDF
42. A population-based study of prognosis and survival in patients with second primary thyroid cancer after Hodgkin lymphoma.
- Author
-
Chowdhry, Amit K., Fung, Chunkit, Chowdhry, Varun K., Bergsma, Derek, Dhakal, Sughosh, Constine, Louis S., and Milano, Michael T.
- Subjects
- *
THYROID cancer , *HODGKIN'S disease , *MORTALITY , *GASTROINTESTINAL agents , *RADIOTHERAPY - Abstract
Hodgkin lymphoma (HL) survivors are at increased risk of thyroid cancer (TC). We sought to determine whether increased risks of high-risk pathology or mortality are seen with thyroid cancer after HL (HL-TC) compared with first primary thyroid cancer (TC-1). From the Surveillance, Epidemiology and End Results (SEER) registry, we compared patient and tumor characteristics as well as survival outcomes between HL-TC and TC-1 and fit a multivariable Cox model to assess for a possible association between HL history and overall survival after TC. Among 139,297 TC-1 and 174 HL-TC patients, history of HL was not associated with anaplastic or sarcoma TC. Multivariable analyzes showed that history of HL was not associated with a difference in risk of death after TC (hazard ratio: 0.96, 95% confidence interval: (0.81, 1.13),
p = .61). Despite a significantly increased risk of TC among HL survivors, prior HL is not associated with more aggressive pathologic subtypes or worse prognosis. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
43. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial.
- Author
-
Kleckner, Ian R, Kamen, Charles, Gewandter, Jennifer S, Mohile, Nimish A, Heckler, Charles E, Culakova, Eva, Fung, Chunkit, Janelsins, Michelle C, Asare, Matthew, Lin, Po-Ju, Reddy, Pavan S, Giguere, Jeffrey, Berenberg, Jeffrey, Kesler, Shelli R, and Mustian, Karen M
- Subjects
TREATMENT of peripheral neuropathy ,ALKALOIDS ,ANTINEOPLASTIC agents ,BREAST tumors ,CLINICAL trials ,COMPARATIVE studies ,EXERCISE therapy ,HYDROCARBONS ,RESEARCH methodology ,MEDICAL cooperation ,PERIPHERAL neuropathy ,ORGANOPLATINUM compounds ,RESEARCH ,RESEARCH funding ,TUMORS ,TUMOR classification ,EVALUATION research ,RANDOMIZED controlled trials - Abstract
Purpose: Over half of all cancer patients receiving taxane-, platinum-, or vinca alkaloid-based chemotherapy experience chemotherapy-induced peripheral neuropathy (CIPN), which includes numbness, tingling, pain, cold sensitivity, and motor impairment in the hands and feet. CIPN is a dose-limiting toxicity, potentially increasing mortality. There are no FDA-approved drugs to treat CIPN, and behavioral interventions such as exercise are promising yet understudied. This secondary analysis of our nationwide phase III randomized controlled trial of exercise for fatigue examines (1) effects of exercise on CIPN symptoms, (2) factors that predict CIPN symptoms, and (3) factors that moderate effects of exercise on CIPN symptoms.Methods: Cancer patients (N = 355, 56 ± 11 years, 93% female, 79% breast cancer) receiving taxane-, platinum-, or vinca alkaloid-based chemotherapy were randomized to chemotherapy or chemotherapy plus Exercise for Cancer Patients (EXCAP©®). EXCAP is a standardized, individualized, moderate-intensity, home-based, six-week progressive walking and resistance exercise program. Patients reported CIPN symptoms of numbness and tingling and hot/coldness in hands/feet (0-10 scales) pre- and post-intervention. We explored baseline neuropathy, sex, age, body mass index, cancer stage, and cancer type as possible factors associated with CIPN symptoms and exercise effectiveness.Results: Exercise reduced CIPN symptoms of hot/coldness in hands/feet (-0.46 units, p = 0.045) and numbness and tingling (- 0.42 units, p = 0.061) compared to the control. Exercise reduced CIPN symptoms more for patients who were older (p = 0.086), male (p = 0.028), or had breast cancer (p = 0.076).Conclusions: Exercise appears to reduce CIPN symptoms in patients receiving taxane-, platinum-, or vinca alkaloid-based chemotherapy. Clinicians should consider prescribing exercise for these patients.Trial Registration: Clinical Trials.gov , # NCT00924651, http://www.clinicaltrials.gov . [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
44. Toxicities Associated with Cisplatin-Based Chemotherapy and Radiotherapy in Long-Term Testicular Cancer Survivors.
- Author
-
Fung, Chunkit, Dinh, Paul, Ardeshir-Rouhani-Fard, Shirin, Schaffer, Kerry, Fossa, Sophie D., Travis, Lois B., and Dinh, Paul Jr.
- Subjects
- *
TESTICULAR cancer treatment , *RADIOTHERAPY , *CANCER chemotherapy , *ADVERSE health care events , *EXERCISE - Abstract
Testicular cancer has become the paradigm of adult-onset cancer survivorship, due to the young age at diagnosis and 10-year relative survival of 95%. This clinical review presents the current status of various treatment-related complications experienced by long-term testicular cancer survivors (TCS) free of disease for 5 or more years after primary treatment. Cardiovascular disease and second malignant neoplasms represent the most common potentially life-threatening late effects. Other long-term adverse outcomes include neuro- and ototoxicity, pulmonary complications, nephrotoxicity, hypogonadism, infertility, and avascular necrosis. Future research efforts should focus on delineation of the genetic underpinning of these long-term toxicities to understand their biologic basis and etiopathogenetic pathways, with the goal of developing targeted prevention and intervention strategies to optimize risk-based care and minimize chronic morbidities. In the interim, health care providers should advise TCS to adhere to national guidelines for the management of cardiovascular disease risk factors, as well as to adopt behaviors consistent with a healthy lifestyle, including smoking cessation, a balanced diet, and a moderate to vigorous intensity exercise program. TCS should also follow national guidelines for cancer screening as currently applied to the general population. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
45. The impact of population pharmacogenomics and risk allele frequencies on cisplatin-induced peripheral sensory neuropathy (PSN).
- Author
-
Nakshatri, Swetha, Dinh, Paul C., Feldman, Darren R., Hamilton, Robert James, Vaughn, David J., Fung, Chunkit, Kollmannsberger, Christian K., Huddart, Robert A, Martin, Neil E., Einhorn, Lawrence H., Cox, Nancy, Travis, Lois B., and Dolan, M. Eileen
- Published
- 2023
- Full Text
- View/download PDF
46. Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.
- Author
-
Chunkit Fung, Sesso, Howard D., Williams, Annalynn M., Kerns, Sarah L., Monahan, Patrick, Zaid, Mohammad Abu, Feldman, Darren R., Hamilton, Robert J., Vaughn, David J., Beard, Clair J., Kollmannsberger, Christian K., Cook, Ryan, Althouse, Sandra, Ardeshir-Rouhani-Fard, Shirin, Lipshultz, Steve E., Einhorn, Lawrence H., Fossa, Sophie D., Travis, Lois B., Fung, Chunkit, and Abu Zaid, Mohammad
- Published
- 2017
- Full Text
- View/download PDF
47. Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin‐Based Chemotherapy for Muscle‐Invasive Bladder Cancer.
- Author
-
Osterman, Chelsea K., Babu, Dilip S., Geynisman, Daniel M., Lewis, Bianca, Somer, Robert A., Balar, Arjun V., Zibelman, Matthew R., Guancial, Elizabeth A., Antinori, Gianna, Yu, Shun, Narayan, Vivek, Guzzo, Thomas J., Plimack, Elizabeth R., Vaughn, David J., Fung, Chunkit, and Mamtani, Ronac
- Subjects
CISPLATIN ,BLADDER tumors ,CANCER invasiveness ,COMBINED modality therapy ,CONFIDENCE intervals ,DRUG administration ,MUSCLE tumors ,TREATMENT effectiveness ,RETROSPECTIVE studies ,ODDS ratio - Abstract
Neoadjuvant cisplatin‐based chemotherapy (NAC; 70 mg/m2) is standard of care for muscle‐invasive bladder carcinoma (MIBC). Many patients (pts) cannot receive cisplatin because of renal impairment, and administration of cisplatin 35 mg/m2 on day 1 + 8 or 1 + 2 (i.e., split schedule) is a commonly used alternative. In this retrospective analysis, we compared complete (pT0) and partial (
- Published
- 2019
- Full Text
- View/download PDF
48. Re: Thyroid hypofunction in aging testicular cancer survivors.
- Author
-
Fung, Chunkit, Dinh Jr., Paul C., and Travis, Lois B.
- Subjects
- *
HYPOGONADISM , *HYPOTHYROIDISM , *CANCER patients , *TESTIS tumors , *AGING - Abstract
The article evaluate the prevalence of thyroid hypofunction among a cohort of Norwegian testicular cancer survivors take advantage of results in a normative Norwegian population as well as linkage to the Norwegian Prescription Database. Topics include testicular cancer diagnosis, the prevalence of thyroid hypofunction was in the testicular cancer survivors; and overall risk of thyroid hypofunction related to the type of cytotoxic testicular cancer treatment with cisplatin-based chemotherapy.
- Published
- 2022
- Full Text
- View/download PDF
49. Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.
- Author
-
Frisina, Robert D., Wheeler, Heather E., Fossa, Sophie D., Kerns, Sarah L., Chunkit Fung, Sesso, Howard D., Monahan, Patrick O., Feldman, Darren R., Hamilton, Robert, Vaughn, David J., Beard, Clair J., Budnick, Amy, Johnson, Eileen M., Ardeshir-Rouhani-Fard, Shirin, Einhorn, Lawrence H., Lipshultz, Steven E., Dolan, M. Eileen, Travis, Lois B., and Fung, Chunkit
- Published
- 2016
- Full Text
- View/download PDF
50. Cardiovascular Disease Mortality After Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study.
- Author
-
Fung, Chunkit, Fossa, Sophie D., Milano, Michael T., Sahasrabudhe, Deepak M., Peterson, Derick R., and Travis, Lois B.
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.